Skip to main content

Table 5 Satisfaction with the decision process 1 by perceived role and by concordance

From: Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey

 

Perceived role

 

Concordance

 
 

Doctor

Shared

Patient

P2

Too little participation

Enough participation

Too much participation

P3

Mean

Mean

Mean

Mean

Mean

Mean

(SD)

(SD)

(SD)

(SD)

(SD)

(SD)

MDM in general (N = 502)

4.0a

4.2a

4.0

.04*

3.9ab

4.2a

4.4b

.00**

(0.8)

(0.7)

(0.6)

(0.8)

(0.7)

(0.5)

(N = 218)

(N = 278)

(N = 6)

(N = 142)

(N = 302)

(N = 52)

Traditional DMARD (N = 332)

3.9a

4.2a

4.3

.00**

3.8ab

4.1a

4.3b

.00**

(0.7)

(0.6)

(0.5)

 

(0.6)

(0.6)

(0.7)

(N = 234)

(N = 90)

(N = 8)

(N = 177)

(N = 141)

(N = 12)

Injecting MTX (N = 137)

3.8a

4.2a

4.0

.02*

3.7ab

4.1a

4.3b

.00**

(0.9)

(0.6)

(0.7)

(0.8)

(0.7)

(0.7)

(N = 53)

(N = 59)

(N = 25)

(N = 41)

(N = 76)

(N = 20)

Biologic agent (N = 131)

4.0

4.3

4.2

.16

4.1

4.3

3.8

.31

(0.8)

(0.6)

(1.6)

(0.9)

(0.7)

(1.2)

(N = 58)

(N = 67)

(N = 6)

(N = 39)

(N = 80)

(N = 10)

Decrease/stop (N = 304)

3.9a

4.1ab

3.8b

.00**

3.8a

4.1ab

3.8b

.00**

(0.8)

(0.6)

(0.8)

(0.8)

(0.7)

(0.8)

(N = 115)

(N = 115)

(N = 74)

(N = 80)

(N = 139)

(N = 84)

  1. MDM = Medical Decision-making; DMARD = Disease Modifying Anti-Rheumatic Drug; MTX = methotrexate.
  2. 1ranging from 1 – 5 in which higher scores indicate more satisfaction.
  3. 2p-levels for differences between doctor, shared and patient, tested with the Kruskal-Wallis test.
  4. 3p-levels for differences between too little, enough and too much participation, tested with the Kruskal-Wallis test.
  5. a or bDistributions are significant different from each other (post hoc test with Mann Whitney with Bonferroni correction).
  6. *Significant on the .05 level.
  7. **Significant on the .01 level.
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us